Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × zimberelimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Lung Neoplasms 3 Stomach Neoplasms 2 Neoplasm Metastasis 2 Cholangiocarcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oligometastatic Prostate Cancer 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Melanoma 1 Locally Advanced Pancreatic Cancer 1 Locally Advanced Cervical Cancer 1 Liver Neoplasms 1 Liposarcoma 1 Kidney Neoplasms 1 Gestational Trophoblastic Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 9 Cisplatin 7 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Nivolumab 4 Etoposide 4 Carboplatin 4 Capecitabine 4 Irinotecan 3 sintilimab 2 pembrolizumab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡